44 results
8-K
EX-99.2
LIANY
LianBio
10 Nov 22
LianBio Reports Third Quarter 2022 Financial Results and Provides Corporate Update
4:16pm
assessment based on RECIST 1.1 mOS 18.1 months mPFS 10.6 months
19 TP-03 for the Treatment of Demodex Blepharitis (DB) and Meibomian Gland Disease (MGD
8-K
EX-99.2
kqjrh3ag 6fyk
11 Aug 22
LianBio Reports Second Quarter 2022 Financial Results and Provides Corporate Update
4:30pm
8-K
EX-99.2
wy43ftnt zl8gv
12 May 22
LianBio Reports First Quarter 2022 Financial Results and Provides Corporate Update
9:15am
DEFR14A
805brz4mpu a8lfm6
28 Apr 22
Revised proxy
5:10pm
DEF 14A
fn22zw
27 Apr 22
Definitive proxy
8:17am
10-K
b0mm02q2 knos
31 Mar 22
Annual report
8:55am
10-K
EX-10.37
f3aib
31 Mar 22
Annual report
8:55am
8-K
EX-99.1
980sj
30 Mar 22
LianBio Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update
4:55pm
8-K
EX-99.1
qkoic itkjw8287duau
2 Mar 22
Regulation FD Disclosure
4:42pm
10-Q
pwr nsxj4
9 Dec 21
Quarterly report
5:24pm
8-K
EX-99.1
fpra ui807
9 Dec 21
LianBio Provides Corporate Update and Reports Third Quarter 2021 Financial Results
4:59pm
424B4
l5q3bamkev5oi6nhmfk6
2 Nov 21
Prospectus supplement with pricing info
4:02pm